Jarushka Naidoo

Academic history

Jarushka Naidoo, MBBCH, MHS, is a prominent Medical Oncologist at Beaumont Hospital, Dublin, Ireland, and works as a Professor at the Royal College of Surgeons (RCSI), Dublin, Ireland. She also serves as the National Lung Cancer Lead for Cancer Trials Ireland, Dublin, Ireland. Prof. Naidoo is an active member of several international guideline panels, including the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC). Her research, which has been supported by substantial grants, has played a crucial role in the development of various clinical trials.

Prof. Naidoo earned her degree in Medicine from Trinity College Dublin, Dublin, Ireland, and completed advanced oncology training at Memorial Sloan Kettering Cancer Center in New York, NY.

Speaking on lung cancer treatments

Prof. Naidoo’s research interests in lung cancer treatment are particularly focused on the application and optimization of immunotherapy. Her work includes post-hoc subgroup analyses from the PACIFIC trial, which investigated the use of durvalumab following chemoradiotherapy (CRT) in patients with unresectable stage III EGFR-mutant non-small cell lung cancer (NSCLC). This analysis provides insights into the efficacy and safety of durvalumab in this specific patient population. Additionally, Prof. Naidoo explores chemotherapy-free and immunotherapy-based treatment approaches for NSCLC, aiming to voice her opinions on treatment regimens by leveraging the latest advances in immunotherapy to improve patient outcomes.